DNA methylation-based biological aging and cancer risk and survival: pooled analysis of seven prospective studies

Pierre Antoine Dugué, Julie K. Bassett, JiHoon E. Joo, Chol Hee Jung, Ee Ming Wong, Margarita Moreno-Betancur, Daniel Schmidt, Enes Makalic, Shuai Li, Gianluca Severi, Allison M. Hodge, Daniel D. Buchanan, Dallas R. English, John L. Hopper, Melissa C. Southey, Graham G. Giles, Roger L. Milne

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The association between aging and cancer is complex. Recent studies have developed measures of biological aging based on DNA methylation and called them “age acceleration.” We aimed to assess the associations of age acceleration with risk of and survival from seven common cancers. Seven case–control studies of DNA methylation and colorectal, gastric, kidney, lung, prostate and urothelial cancer and B-cell lymphoma nested in the Melbourne Collaborative Cohort Study were conducted. Cancer cases, vital status and cause of death were ascertained through linkage with cancer and death registries. Conditional logistic regression and Cox models were used to estimate odds ratios (OR) and hazard ratios (HR) and 95% confidence intervals (CI) for associations of five age acceleration measures derived from the Human Methylation 450 K Beadchip assay with cancer risk (N = 3,216 cases) and survival (N = 1,726 deaths), respectively. Epigenetic aging was associated with increased cancer risk, ranging from 4% to 9% per five-year age acceleration for the 5 measures considered. Heterogeneity by study was observed, with stronger associations for risk of kidney cancer and B-cell lymphoma. An associated increased risk of death following cancer diagnosis ranged from 2% to 6% per five-year age acceleration, with no evidence of heterogeneity by cancer site. Cancer risk and mortality were increased by 15–30% for the fourth versus first quartile of age acceleration. DNA methylation-based measures of biological aging are associated with increased cancer risk and shorter cancer survival, independently of major health risk factors.

Original languageEnglish
Pages (from-to)1611-1619
Number of pages9
JournalInternational Journal of Cancer
Volume142
Issue number8
DOIs
Publication statusPublished - 15 Apr 2018
Externally publishedYes

Keywords

  • age acceleration
  • aging
  • biological age
  • blood
  • DNA methylation
  • epigenetic aging
  • epigenetic clock
  • lymphoma
  • prospective study
  • survival

Cite this

Dugué, Pierre Antoine ; Bassett, Julie K. ; Joo, JiHoon E. ; Jung, Chol Hee ; Ming Wong, Ee ; Moreno-Betancur, Margarita ; Schmidt, Daniel ; Makalic, Enes ; Li, Shuai ; Severi, Gianluca ; Hodge, Allison M. ; Buchanan, Daniel D. ; English, Dallas R. ; Hopper, John L. ; Southey, Melissa C. ; Giles, Graham G. ; Milne, Roger L. / DNA methylation-based biological aging and cancer risk and survival : pooled analysis of seven prospective studies. In: International Journal of Cancer. 2018 ; Vol. 142, No. 8. pp. 1611-1619.
@article{36655bfb923c4e3d8d6faaa834b9597d,
title = "DNA methylation-based biological aging and cancer risk and survival: pooled analysis of seven prospective studies",
abstract = "The association between aging and cancer is complex. Recent studies have developed measures of biological aging based on DNA methylation and called them “age acceleration.” We aimed to assess the associations of age acceleration with risk of and survival from seven common cancers. Seven case–control studies of DNA methylation and colorectal, gastric, kidney, lung, prostate and urothelial cancer and B-cell lymphoma nested in the Melbourne Collaborative Cohort Study were conducted. Cancer cases, vital status and cause of death were ascertained through linkage with cancer and death registries. Conditional logistic regression and Cox models were used to estimate odds ratios (OR) and hazard ratios (HR) and 95{\%} confidence intervals (CI) for associations of five age acceleration measures derived from the Human Methylation 450 K Beadchip assay with cancer risk (N = 3,216 cases) and survival (N = 1,726 deaths), respectively. Epigenetic aging was associated with increased cancer risk, ranging from 4{\%} to 9{\%} per five-year age acceleration for the 5 measures considered. Heterogeneity by study was observed, with stronger associations for risk of kidney cancer and B-cell lymphoma. An associated increased risk of death following cancer diagnosis ranged from 2{\%} to 6{\%} per five-year age acceleration, with no evidence of heterogeneity by cancer site. Cancer risk and mortality were increased by 15–30{\%} for the fourth versus first quartile of age acceleration. DNA methylation-based measures of biological aging are associated with increased cancer risk and shorter cancer survival, independently of major health risk factors.",
keywords = "age acceleration, aging, biological age, blood, DNA methylation, epigenetic aging, epigenetic clock, lymphoma, prospective study, survival",
author = "Dugu{\'e}, {Pierre Antoine} and Bassett, {Julie K.} and Joo, {JiHoon E.} and Jung, {Chol Hee} and {Ming Wong}, Ee and Margarita Moreno-Betancur and Daniel Schmidt and Enes Makalic and Shuai Li and Gianluca Severi and Hodge, {Allison M.} and Buchanan, {Daniel D.} and English, {Dallas R.} and Hopper, {John L.} and Southey, {Melissa C.} and Giles, {Graham G.} and Milne, {Roger L.}",
year = "2018",
month = "4",
day = "15",
doi = "10.1002/ijc.31189",
language = "English",
volume = "142",
pages = "1611--1619",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Blackwell",
number = "8",

}

DNA methylation-based biological aging and cancer risk and survival : pooled analysis of seven prospective studies. / Dugué, Pierre Antoine; Bassett, Julie K.; Joo, JiHoon E.; Jung, Chol Hee; Ming Wong, Ee; Moreno-Betancur, Margarita; Schmidt, Daniel; Makalic, Enes; Li, Shuai; Severi, Gianluca; Hodge, Allison M.; Buchanan, Daniel D.; English, Dallas R.; Hopper, John L.; Southey, Melissa C.; Giles, Graham G.; Milne, Roger L.

In: International Journal of Cancer, Vol. 142, No. 8, 15.04.2018, p. 1611-1619.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - DNA methylation-based biological aging and cancer risk and survival

T2 - pooled analysis of seven prospective studies

AU - Dugué, Pierre Antoine

AU - Bassett, Julie K.

AU - Joo, JiHoon E.

AU - Jung, Chol Hee

AU - Ming Wong, Ee

AU - Moreno-Betancur, Margarita

AU - Schmidt, Daniel

AU - Makalic, Enes

AU - Li, Shuai

AU - Severi, Gianluca

AU - Hodge, Allison M.

AU - Buchanan, Daniel D.

AU - English, Dallas R.

AU - Hopper, John L.

AU - Southey, Melissa C.

AU - Giles, Graham G.

AU - Milne, Roger L.

PY - 2018/4/15

Y1 - 2018/4/15

N2 - The association between aging and cancer is complex. Recent studies have developed measures of biological aging based on DNA methylation and called them “age acceleration.” We aimed to assess the associations of age acceleration with risk of and survival from seven common cancers. Seven case–control studies of DNA methylation and colorectal, gastric, kidney, lung, prostate and urothelial cancer and B-cell lymphoma nested in the Melbourne Collaborative Cohort Study were conducted. Cancer cases, vital status and cause of death were ascertained through linkage with cancer and death registries. Conditional logistic regression and Cox models were used to estimate odds ratios (OR) and hazard ratios (HR) and 95% confidence intervals (CI) for associations of five age acceleration measures derived from the Human Methylation 450 K Beadchip assay with cancer risk (N = 3,216 cases) and survival (N = 1,726 deaths), respectively. Epigenetic aging was associated with increased cancer risk, ranging from 4% to 9% per five-year age acceleration for the 5 measures considered. Heterogeneity by study was observed, with stronger associations for risk of kidney cancer and B-cell lymphoma. An associated increased risk of death following cancer diagnosis ranged from 2% to 6% per five-year age acceleration, with no evidence of heterogeneity by cancer site. Cancer risk and mortality were increased by 15–30% for the fourth versus first quartile of age acceleration. DNA methylation-based measures of biological aging are associated with increased cancer risk and shorter cancer survival, independently of major health risk factors.

AB - The association between aging and cancer is complex. Recent studies have developed measures of biological aging based on DNA methylation and called them “age acceleration.” We aimed to assess the associations of age acceleration with risk of and survival from seven common cancers. Seven case–control studies of DNA methylation and colorectal, gastric, kidney, lung, prostate and urothelial cancer and B-cell lymphoma nested in the Melbourne Collaborative Cohort Study were conducted. Cancer cases, vital status and cause of death were ascertained through linkage with cancer and death registries. Conditional logistic regression and Cox models were used to estimate odds ratios (OR) and hazard ratios (HR) and 95% confidence intervals (CI) for associations of five age acceleration measures derived from the Human Methylation 450 K Beadchip assay with cancer risk (N = 3,216 cases) and survival (N = 1,726 deaths), respectively. Epigenetic aging was associated with increased cancer risk, ranging from 4% to 9% per five-year age acceleration for the 5 measures considered. Heterogeneity by study was observed, with stronger associations for risk of kidney cancer and B-cell lymphoma. An associated increased risk of death following cancer diagnosis ranged from 2% to 6% per five-year age acceleration, with no evidence of heterogeneity by cancer site. Cancer risk and mortality were increased by 15–30% for the fourth versus first quartile of age acceleration. DNA methylation-based measures of biological aging are associated with increased cancer risk and shorter cancer survival, independently of major health risk factors.

KW - age acceleration

KW - aging

KW - biological age

KW - blood

KW - DNA methylation

KW - epigenetic aging

KW - epigenetic clock

KW - lymphoma

KW - prospective study

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85038218146&partnerID=8YFLogxK

U2 - 10.1002/ijc.31189

DO - 10.1002/ijc.31189

M3 - Article

VL - 142

SP - 1611

EP - 1619

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 8

ER -